Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma

Clinical and Experimental Metastasis

Volumn 29, Issue 4, 2012, Pages 339-347

  Bosch, Rosa ^a,b   Moreno, María José ^a   Dieguez Gonzalez, Rebeca ^a   Céspedes, María Virtudes ^a,b   Gallardo, Alberto ^c   Nomdedeu, Josep ^d   Pavón, Miguel Ángel ^a,b   Espinosa, Iñigo ^d   Mangues, Maria Antònia ^d   Sierra, Jorge ^d   Casanova, Isolda ^a,b   Mangues, Ramon ^a,b  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

AKT; DLBCL; Focal adhesions; Subcutaneous passage; Xenograft model

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER MODEL; CELL INFILTRATION; CELL SUSPENSION; CONTROLLED STUDY; DISSEMINATED CANCER; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPH NODE CELL; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE; TUMOR ENGRAFTMENT; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84859709820     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9454-8     Document Type: Article

References (35)

1. Coiffier B (2005) State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 23:6387-6393
2. Matasar MJ, Zelenetz AD (2008) Overview of lymphoma diagnosis and management. Radiol Clin North Am 46:175-198 (Pubitemid 351932045)
3. O'Connor OA, Toner LE, Vrhovac R et al (2005) Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches. Leuk Lymphoma 46:973-992 (Pubitemid 40975017)
4. Ghetie MA, Richardson J, Tucker T et al (1990) Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer 45:481-485 (Pubitemid 20087196)
5. Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ (2001) Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. Clin Cancer Res 7:1505-1510 (Pubitemid 32708612)
6. Griffiths GL, Mattes MJ, Stein R et al (2003) Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 9:6567-6571 (Pubitemid 38031846)
7. DiJoseph JF, Dougher MM, Kalyandrug LB et al (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 12:242-249 (Pubitemid 43166200)
8. Zhao XF, Hassan A, Perry A et al (2008) C-MYC rearrangements are frequent in aggressive mature B-cell lymphoma with atypical morphology. Int J Clin Exp Pathol 1:65-74
9. Maximova OA, Taffs RE, Pomeroy KL, Piccardo P, Asher DM (2006) Computerized morphometric analysis of pathological prion protein deposition in scrapie-infected hamster brain. J Histochem Cytochem 54:97-107 (Pubitemid 43049419)
10. Casanova I, Bosch R, Lasa A et al (2008) A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells. Int J Cancer 123:217-226 (Pubitemid 351705212)
11. Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242:148-149
12. Andreassen K, Mortensen B, Winberg JO, Huseby NE (2002) Increased resistance towards oxidative stress accompanies enhancement of metastatic potential obtained by repeated in vivo passage of colon carcinoma cells in syngeneic rats. Clin Exp Metastasis 19:623-629 (Pubitemid 35454573)
13. Yasoshima T, Denno R, Kawaguchi S et al (1996) Establishment and characterization of human gastric carcinoma lines with high metastatic potential in the liver: changes in integrin expression associated with the ability to metastasize in the liver of nude mice. Jpn J Cancer Res 87:153-160
14. Bresalier RS, Hujanen ES, Raper SE et al (1987) An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res 47:1398-1406 (Pubitemid 17023214)
15. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA (2004) Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem 279:33024-33034 (Pubitemid 39014762)
16. Yan JS, Chen XY, Li WP, Yang Y, Song ZL (2009) Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma. Ai Zheng 28:181-183
17. Cattoretti G, Pasqualucci L, Ballon G et al (2005) Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7:445-455 (Pubitemid 40719128)
18. Hoyer KK, French SW, Turner DE et al (2002) Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 99:14392-14397 (Pubitemid 35257682)
19. Ranger AM, Zha J, Harada H et al (2003) Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100:9324-9329 (Pubitemid 37033927)
20. Richmond A, Su Y (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1:78-82
21. Gatter K, Pezzella F (2009) Diffuse large B-cell lymphoma. Diagn histopathol 16:69-75
22. Aubert C (1995) Metastatic variants of the B16 melanoma: metastasis is related to environmental conditions. Phenotypic changes in vitro and metastatic colonization potential in nude mice. Melanoma Res 5:139-146
23. Seftor EA, Meltzer PS, Kirschmann DA et al (2006) The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10:174-196 (Pubitemid 44874300)
24. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22
25. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285:1028-1032
26. Sarkar S, Svoboda M, de Beaumont R, Freedman AS (2002) The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk Lymphoma 43:1663-1671 (Pubitemid 34823488)
27. Uddin S, Hussain AR, Siraj AK et al (2006) Role of phosphatidylinositol 30-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108:4178-4186 (Pubitemid 44913290)
28. Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S (2008) Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol 17:159-165
29. Bosch R, Dieguez-Gonzalez R, Céspedes MV et al (2011) A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma. Blood 118:4411-4420
30. Kim M, Gans JD, Nogueira C et al (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-1281 (Pubitemid 43949521)
31. Miyazaki T, Kato H, Nakajima M et al (2003) FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 89:140-145 (Pubitemid 36903212)
32. Sood AK, Coffin JE, Schneider GB et al (2004) Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 165:1087-1095 (Pubitemid 39297716)
33. Earley S, Plopper GE (2008) Phosphorylation of focal adhesion kinase promotes extravasation of breast cancer cells. Biochem Biophys Res Commun 366:476-482
34. Shibue T, Weinberg RA (2009) Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 106:10290-10295
35. Fromont G, Vallancien G, Validire P, Levillain P, Cussenot O (2007) BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate 67:268-273